Related Experiment Video
Updated: Jun 2, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic
Zahra Amirghofran1, Yahya Daneshbod, Naser Gholijani
1Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. amirghz@sums.ac.ir
Background:
The possible prognostic significance of the expression of a variety of markers has been investigated in acute lymphoblastic leukemia (ALL).
Methods:
In the present study we investigated the prognostic significance of CD13 and CD33 myeloid antigens (MY) aberrantly expressed on the blasts of ALL patients and Bcl-2 anti- apoptotic molecule expression in childhood ALL.
Results:
Aberrant expression of MY occurred in 8.8% of cases. Variant levels of Bcl-2 were expressed in patients (44.2±25.5%), with more than 20% positivity for Bcl-2 in 64.7% of patients. Bcl-2+ patients survived 959±242 days compared to 1059+230 days for Bcl-2- patients (P=0.2). Corresponding data for complete remission duration was 682±170 and 716±173 days (P=0.3), respectively, indicating no significant association between survival and complete remission duration of patients with expression of the Bcl-2 molecule. Analysis of clinical response according to MY expression, however, showed significant association with survival and complete remission duration. MY+ patients had shorter complete remission duration (383±58 days) and survival (473±68 days) than MY- patients (complete remission duration, 724±144 days; survival, 1045±186 days; P<0.001). Expression of Bcl-2 along with MY was not associated with a significant decrease in survival or complete remission duration.
Conclusion:
Results of this study indicated that expression of MY was a poor prognostic factor in childhood ALL. Bcl-2 expression in MY+ patients could not influence the response to therapy.
